Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Trial Profile

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Constipation; Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 10 Jul 2020 Results of pooled analysis from four Phase III trials in CIC and IBS-C (NCT01982240, NCT02122471, NCT02387359, and NCT02493452) to assess the safety and efficacy of plecanatide in patients aged more than 65 years, published in the Clinical Therapeutics.
    • 19 May 2020 Results of post hoc analysis from 4 randomized, phase 3 studies (2 CIC and 2 IBS-C) assessing the impact of plecanatide on abdominal pain,published at the Digestive Disease Week 2020
    • 19 May 2020 Results, pooled analysis of data from 4 studies (2 CIC and 2 IBS-C) assessing symptoms responses by baseline bloating severity, published in Gastroenterology in conjunction with Digestive Disease Week 2020
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top